News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
AlphaMed Release: PET/CT And Biomarkers Predict Treatment Response In Metastatic Colon Cancer
1/22/2014 10:46:10 AM
Durham, NC – A new study published online today in The Oncologist journal shows that an assessment of metabolic response in patients with metastatic colon cancer (mCC) treated with a single course of chemotherapy could predict the downstream efficacy of the treatment. A team of researchers from various institutions in Denmark, led by Bodil Engelmann, MD, at Næstved Hospital in Copenhagen, performed a prospective, monocentric study to determine the predictive value of a number of established biomarkers as well as the results of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in the early response of mCC to treatment with widely used chemotherapeutic drugs.
Colorectal cancer (CRC) is one of the deadliest malignancies worldwide, with about a quarter of patients presenting with malignant disease upon initial diagnosis. Despite a growing number of therapeutic regimens for the disease, the 5-year survival remains low at less than 10%. Given the variety of treatment options, improving clinicians’ ability to predict patients’ responses to various treatments would allow them to alter the therapeutic course for patients with unresponsive tumors. This new study suggests an approach that overcomes some of the limitations of the current gold standards for disease assessment, which are either limited to treatments that ultimately affect tumor size or those that cannot be applied, in many cases, until three months have elapsed after treatment.
A total of 26 mCC patients from a single hospital completed the study, which involved pretreatment PET/CT and treatment with repeating cycles of capecitabine/oxaliplatin (CAPOX) and bevacizumab. Early and late PET/CT evaluations were performed, as well as peripheral blood collection at 20 days after the first treatment cycle and 20 days after the fourth cycle. In addition to functional imaging using FDG PET/CT, the group assessed the levels of the glycoprotein carcinoembryonic antigen (CEA), tissue inhibitor of metalloproteinases-1 (TIMP-1), liberated domain 1 of urokinase plasminogen activator receptor [uPAR(I)] and the mutation status of KRAS and BRAF oncogenes, all of which are known predictors of treatment response and/or prognosis.
When patients were divided into responders and nonresponders, the early metabolic response category assessed by PET could predict the late morphological response category determined by CT in 73% of cases, with 80% sensitivity and 69% specificity. Early determination of metabolic nonresponse was significantly predictive of disease progression, with nonresponders having a greater than 3 times higher risk of progression compared to responders. A nonsignificant reduction in overall survival was also observed among metabolic nonresponders compared with responders, according to early PET evaluation. A 10-mm diameter increase in the largest lesion observed at pretreatment PET/CT was significantly predictive of poorer survival, as was the number of metastatic sites observed. High levels of TIMP-1 at both pretreatment and early post-treatment evaluations were significantly associated with an increased risk of death. Additionally, treatment significantly decreased TIMP-1 levels at the early evaluation. While CEA levels were characteristically high in almost all the mCC cases, there was no association between their levels and patient survival, although CEA did decrease following treatment in a borderline statistically significant manner. Finally, high uPAR(I) levels at both pretreatment and early evaluation were predictive of poorer survival, and the levels of this biomarker also decreased after treatment.
The group’s findings have the potential to alter the approach to palliative treatment for mCC by allowing clinicians to anticipate unfavorable outcomes soon after treatment initiation. According to Dr. Engelmann, "Metabolic therapy response assessed by FDG PET/CT after only one treatment series identifies patients with mCC that do not show radiologically detectable tumor shrinkage after four treatment series. FDG-PET/CT can help to assign these patients to more effective treatments early in the course of their disease."
Otto S. Hoekstra, MD, a member of The Oncologist’s editorial board, noted, “Biomarkers to predict therapy response are essential to optimize personalized medicine. The Engelmann study showed that PET, applied after a single cycle of first-line systemic therapy predicted progression-free survival. These findings on the potential impact of in vitro biomarkers including TIMP-1 and uPAR(I) should stimulate research on the potentially additive value of combined in vivo and in vitro biomarkers.”
About The Oncologist
Established by oncologists to help physicians better manage their practices in an ever-changing environment, The Oncologist® is the official journal of the Society for Translational Oncology (STO). Now in its 19th year, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment, and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. For more information, visit www.TheOncologist.com.
About AlphaMed Press
Established in 1983, AlphaMed Press, with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (www.StemCells.com), which celebrates its 32nd year in 2014, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), entering its 19th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (www.StemCellsTM.com), in its third year, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
Help employers find you! Check out all the jobs and post your resume.